Inventor · disambiguated record
Reshma Singh
Also filed as: SINGH RESHMA
15 granted patents·5 pending applications·259 citations·filing 2004–2025
93Inventor score
Top patents by PatentIndex Score
20 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9777061B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Oct 3, 2017·85 cites·24 claims
- 0395US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0495US7820180B2Listeria-based and LLO-based vaccinesUNIV PENNSYLVANIA·Filed 2005·Granted Oct 26, 2010·25 cites·62 claims
- 0591US7662396B2Compositions and methods for enhancing the immunogenicity of antigensUNIV PENNSYLVANIA·Filed 2006·Granted Feb 16, 2010·30 cites·31 claims
- 0688US9463227B2Listeria-based adjuvantsROTHMAN JOHN·Filed 2012·Granted Oct 11, 2016·18 cites·15 claims
- 0787US10064898B2Listeria-based adjuvantsADVAXIS INC·Filed 2016·Granted Sep 4, 2018·7 cites·14 claims
- 0887US7794729B2Methods and compositions for immunotherapy of cancerUNIV PENNSYLVANIA·Filed 2004·Granted Sep 14, 2010·23 cites·15 claims
- 0986US11413340B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2016·Granted Aug 16, 2022·2 cites·32 claims
- 1085US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 1182US10851166B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Dec 1, 2020·1 cites·22 claims
- 1280US10058599B2Suppressor cell function inhibition following Listeria vaccine treatmentADVAXIS INC·Filed 2013·Granted Aug 28, 2018·6 cites·14 claims
- 1379US2025353916A1Treatment of cancer using a cd33 chimeric antigen receptorNOVARTIS AG·Filed 2025·Application pending·0 cites
- 1476US12186278B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2022·Granted Jan 7, 2025·0 cites·27 claims
- 1570US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 1669US12338287B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Jun 24, 2025·0 cites·24 claims
- 1766US2025319179A1Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 1865US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1957US2008124354A1Methods for administering tumor vaccinesPATERSON YVONNE·Filed 2007·Application pending·0 cites
- 2043US2018153974A1Combination Therapies With Recombinant Listeria StrainsUNIV PENNSYLVANIA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Reshma Singh files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →